洛铂联合重组白介素-2腹腔灌注治疗癌性腹水的效果及安全性分析

Abstract
Figure/Table
References (18)
Related Citation (0)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the efficacy and safety analysis of Lobaplatin combined with Recombinant Interleukin-2 peritoneal injection for the treatment of malignant ascites.Methods34 patients with malignant ascites from March 2015 to March 2017 treated in our hospital were selected as subjects,and they were divided into two groups according to the number of singular or double digits of the admission date,17 cases in each group.The control group was treated with 50 ml of Physiological Saline,60～100 mg of Lobaplatin and 10 mg of Dexamethasone with peritoneal perfusion,the observation group was treated with 50 ml of Physiological Saline,60～100 mg of Lobaplatin,10 mg of Dexamethasone and 1 million U Interleukin-2 with peritoneal perfusion.The clinical efficacy,quality of life (KPS)scores and adverse effects of the two groups were compared.ResultsThe total efficiency of treatment was compared between the two groups,and the difference was not statistically significant(P＞0.05).The proportion of improvement of KPS score in the observation group was higher than that in the control group,and the proportion of decrease was lower than that in the control group,and the differences were statistically significant(P＜0.05).The occurrence of adverse effects were compared between the two groups,the differences were not statistically significant(P＞0.05),and the incidence of leukocyte reduction and bone marrow suppression were higher in both groups,and the incidence of other adverse effects were lower.ConclusionThe treatment of malignant ascite with Lobaplatin combined with Recombinant Interleukin-2 peritoneal injection can improve the clinical efficacy and improve the quality of life of patients.

Key words： Malignant ascites Lobaplatin Interleukin-2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZOU Cai-liang
	WANG Hong-yun
	WU Yan-ling
	XIA Xiao-long

Cite this article:

ZOU Cai-liang,WANG Hong-yun,WU Yan-ling, et al. The efficacy and safety analysis of Lobaplatin combined with Recombinant Interleukin-2 peritoneal injection for the treatment of malignant ascites[J]. 中国当代医药, 2017, 24(35): 131-133转137.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I35/131

[1]	胡霞，潘迎英.癌性腹水治疗的研究进展[J].内蒙古中医药，2013，32（25）:128-130.
[2]	匡树根，刘霞，刘铁兵，等.热疗加腹腔热灌注化疗治疗恶性腹水的临床研究[J].当代医学，2016，22（18）:13-14.
[3]	邢雪花，王琳，盛莉，等.顺铂或洛铂腹腔化疗联合微波热疗治疗癌性腹水的临床观察[J].中华肿瘤防治杂志，2014，21（17）:1376-1378.
[4]	水会锋.多西他赛联合腹腔内洛铂灌注并配合腹部热疗治疗卵巢癌腹腔积液临床疗效[J].北方药学，2017，14（2）:46-47.
[5]	邓正兴.腹腔灌注顺铂联合口服替吉奥治疗胃癌合并恶性腹水的效果及安全性分析[J].中国当代医药，2015，22（26）:49-51.
[6]	武海涛，杨肖军，孙建华，等.洛铂联合多西他赛行肿瘤细胞减灭术加腹腔热灌注化疗治疗腹膜癌的临床观察[J].肿瘤防治研究，2016，43（2）:150-157.
[7]	高云，闫新欣，张然，等.洛铂对比白介素-2治疗恶性胸腔积液的临床观察及安全性研究[J].中国临床医生杂志，2016，44（7）:60-62.
[8]	张桂枫，崔同建，刘振华.洛铂联合重组人血管内皮抑素腹腔灌注治疗癌性腹腔积液25例疗效观察[J].福建医药杂志，2016，38（6）:122-124.
[9]	李光，刘洪霞，刘军.洛铂与奥沙利铂腹腔热灌注化疗治疗腹膜转移胃腺癌的疗效和安全性比较[J].胃肠病学和肝病学杂志，2017，26（3）:266-270.
[10]	贺玉卿，高立明，高庆壮，等.腹腔灌注重组人血管内皮抑素联合洛铂射频热疗对恶性腹腔积液患者VEGF及生活质量的影响[J].实用临床医药杂志，2016，20（5）:53-56.
[11]	侯仰韶，时红萍.热疗联合腹腔热灌注化疗治疗恶性腹水疗效与安全性的Meta分析[J].中国循证医学杂志，2013，13（10）:9-14.
[12]	王涛，杨俊省.紫杉醇联合洛铂同期放疗治疗中晚期食管癌的临床近期疗效及安全性[J].国际肿瘤学杂志，2015，42（1）:10-13.
[13]	陈康，马金山，努尔兰，等.aAd-p53基因靶向治疗癌性胸腹水的临床效果分析[J].现代生物医学进展，2014，14（33）:6476-6478.
[14]	高云，闫新欣，张然，等.洛铂对比白介素-2治疗恶性胸腔积液的临床观察及安全性研究[J].中国临床医生杂志，2016，44（7）:60-62.
[15]	陈珑，黄平，张相杰，等.伊立替康联合洛铂对依托泊苷方案化疗失败小细胞肺癌肝转移患者的疗效及安全性评价[J].河北医药，2016，38（20）:3098-3100.
[16]	峗淑莉，朱模寿，刘振海，等.洛铂联合紫杉醇治疗晚期非小细胞肺癌的疗效与安全性研究[J].中国当代医药，2016，23（32）:73-75.
[17]	王立伟，刘耀捷，魏秀芹，等.毫米波联合奈达铂循环热灌注化疗治疗恶性腹腔积液的临床疗效及对骨髓抑制的影响[J].临床和实验医学杂志，2016，13（13）:1294-1297.
[18]	葛婷，周建伟，潘龙赐，等.复方苦参注射液联合自制消臌散治疗恶性腹腔积液的临床研究[J].临床和实验医学杂志，2017，16（2）:148-151.